BEST of ASCO 2024 - LB
Abstract
In non-small cell lung cancer (NSCLC), therapies directed at molecular targets have been one of the areas with the greatest growth, with numerous trials reporting new results and many others still in progress. At this year's ASCO congress, 4 studies related to the treatment of patients with the ALK rearrangement, the KRAS G12C mutation and the EGFR mutation stood out.
Downloads
References
Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47.
Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nat Cancer. 2023 Mar;4(3):330-343.
Yu HA, Sima CS, Shen R, et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015 Mar;10(3):431-7.
Cho BC, Simi A, Sabari J, et al. Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications. Clin Lung Cancer. 2023 Mar;24(2):89-97.
